[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Erasca Inc (ERAS)

Erasca Inc (ERAS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,246,750
  • Shares Outstanding, K 349,762
  • Annual Sales, $ 0 K
  • Annual Income, $ -124,550 K
  • EBIT $ -293 M
  • EBITDA $ -295 M
  • 60-Month Beta 0.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 14.68

Options Overview Details

View History
  • Implied Volatility 100.74% (-8.19%)
  • Historical Volatility 60.16%
  • IV Percentile 20%
  • IV Rank 6.64%
  • IV High 404.74% on 09/16/25
  • IV Low 79.11% on 05/19/26
  • Expected Move (DTE 7) 1.63 (9.05%)
  • Put/Call Vol Ratio 0.41
  • Today's Volume 254
  • Volume Avg (30-Day) 1,644
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 161,139
  • Open Int (30-Day) 152,982
  • Expected Range 16.41 to 19.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.13
  • Number of Estimates 5
  • High Estimate $-0.11
  • Low Estimate $-0.14
  • Prior Year $-0.11
  • Growth Rate Est. (year over year) -18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.08 +5.71%
on 08/03/26
21.60 -16.41%
on 07/15/26
-1.44 (-7.41%)
since 07/14/26
3-Month
9.95 +81.46%
on 05/15/26
21.60 -16.41%
on 07/15/26
+7.69 (+74.11%)
since 05/14/26
52-Week
1.33 +1,257.42%
on 09/03/25
24.28 -25.64%
on 04/23/26
+16.49 (+1,050.00%)
since 08/14/25

Most Recent Stories

More News
Erasca Reports Second Quarter 2026 Business Updates and Financial Results

Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination...

ERAS : 18.05 (+1.06%)
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 18.05 (+1.06%)
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Erasca, Inc. (“Erasca” or “the Company”) (NASDAQ:...

ERAS : 18.05 (+1.06%)
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Erasca To Contact Him Directly To Discuss Their Options...

ERAS : 18.05 (+1.06%)
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline

SAN FRANCISCO , Aug. 10, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights firm, is actively investigating claims in a class action alleging securities law violations at Erasca, Inc....

ERAS : 18.05 (+1.06%)
Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D

SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 18.05 (+1.06%)
Erasca, Inc. Investor Alert: Contact SBS by August 10, 2026 for Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , Aug. 10, 2026 /PRNewswire/ -- Schall Brown & Schwartz LLP , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Erasca, Inc. ("Erasca"...

ERAS : 18.05 (+1.06%)
Erasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS

LOS ANGELES , Aug. 10, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Erasca, Inc. ("Erasca" or "the Company") (NASDAQ: ERAS ) for violations...

ERAS : 18.05 (+1.06%)
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline

SAN FRANCISCO , Aug. 9, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights firm, is actively investigating claims in a class action alleging securities law violations at Erasca, Inc....

ERAS : 18.05 (+1.06%)
Erasca 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Erasca, Inc. - ERAS

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 10, 2026 ...

ERAS : 18.05 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Erasca Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 19.80
2nd Resistance Point 19.38
1st Resistance Point 18.62
Last Price 18.05
1st Support Level 17.44
2nd Support Level 17.02
3rd Support Level 16.26

See More

52-Week High 24.28
Last Price 18.05
Fibonacci 61.8% 15.51
Fibonacci 50% 12.81
Fibonacci 38.2% 10.10
52-Week Low 1.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.